Aprocitentan, a dual endothelin-1 (ET-1) antagonist for treating resistant hypertension: Mechanism of action and therapeutic potential
Author:
Funder
Queen Mary University of London
National Natural Science Foundation of China
Publisher
Elsevier BV
Subject
Drug Discovery,Pharmacology
Reference61 articles.
1. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries;Mills;Circulation,2016
2. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019;GBD 2019 Risk Factors Collaborators;Lancet,2020
3. 2020 international society of hypertension global hypertension practice guidelines;Unger;Hypertension,2020
4. Hypertension;Oparil;Nat Rev Dis Primers,2018
Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. A review of novel endothelin antagonists and overview of non-steroidal mineralocorticoid antagonists for treating resistant hypertension: An update;European Journal of Pharmacology;2024-09
2. Bosentan and Pulmonary Hypertension Caused by COVID-19: A Pilot Randomized Double-blind Clinical Study;Current Vascular Pharmacology;2024-06-13
3. How New Developments in Pharmacology Receptor Theory Are Changing (Our Understanding of) Hypertension Therapy;American Journal of Hypertension;2023-12-27
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3